Indo US Bio-Tech Ltd

On 28 Nov, Indo US Bio-Tech Ltd witnessed a significant drop in its share price, falling by 8.02% to close at ₹135.90. This decline followed two consecutive days of gains and was accompanied by heightened volatility and increased investor participation, signalling a notable shift in market sentiment.

Indo US Bio-Tech has shown steady growth over the past three years, with net sales increasing from 39.76 crore in March 2020 to 50.06 crore in March 2022, and profit after tax rising from 2.53 crore to 5.06 crore. Despite rising raw material costs, the company improved its operational efficiency and cash flow during this period.

As of November 17, 2025, Indo US Bio-Tech is considered very attractive and undervalued compared to peers, with a PE ratio of 14.72, an EV to EBITDA ratio of 13.32, and a PEG ratio of 0.34, despite a year-to-date stock decline of 60.67%.

As of 17-Nov, Indo US Bio-Tech Ltd's stock price is Rs 123.90, down 3.88% and close to its 52-week low. Despite positive financial results, the stock has underperformed significantly compared to the market, reflecting low investor participation and a year-to-date decline of 60.67%.

Indo US Bio-Tech has shown steady growth in net sales and profitability over the past three years, with net sales rising from 39.76 Cr in March 2020 to 50.06 Cr in March 2022, and profit after tax increasing from 2.53 Cr to 5.06 Cr. Despite rising raw material costs, the company improved its operational efficiency and achieved positive cash flow from operating activities in March 2022.

Indo US Bio-Tech has shown steady growth in net sales and profitability over the past three years, with net sales rising from 39.76 Cr in March 2020 to 50.06 Cr in March 2022, and operating profit improving from 3.99 Cr to 6.95 Cr. Despite increased raw material costs, the company achieved positive cash flow from operating activities in March 2022.

As of November 10, 2025, Indo US Bio-Tech is considered an attractive investment due to its undervaluation compared to peers, with a PE ratio of 14.64, a strong ROE of 22.66%, and significant growth potential, despite recent stock performance lagging behind the Sensex.

Indo US Bio-Tech will announce its results on 14 November 2025.

As of 06-Nov, Indo US Bio-Tech Ltd's stock price is Rs 130.70, down 3.97%, and has underperformed its sector and the Sensex. The stock is in a bearish trend, trading below key moving averages, with a year-to-date return of -58.51%.

Indo US Bio-Tech has shown steady growth in net sales and profits over the past three years, with net sales increasing from 39.76 Cr in March 2020 to 50.06 Cr in March 2022, despite rising raw material costs. The company’s profit before tax rose to 5.31 Cr in March 2022, up from 2.86 Cr in March 2020, indicating consistent operational efficiency and profitability.